Safety and Efficacy Study of Bimosiamose Cream to Treat Psoriasis

Revotar Biopharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Psoriasis

Treatments: Drug: Placebo Cream; Drug: Bimosiamose Cream

Study type: Interventional

Funder types: Industry

Identifiers

NCT00823693

R013

Details and patient eligibility

About

The purpose of this study is to determine whether Bimosiamose Cream is safe and effective in the treatment of plaque type psoriasis.

Enrollment: 107 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of plaque type psoriasis PASI score of 5-15
• At least 18 years of age
• Written informed consent

Exclusion criteria

• Active skin infection
• More than 20% Body Surface Area (BSA) affected by psoriasis
• Use of certain anti-psoriasis medication or treatments

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

107 participants in 2 patient groups, including a placebo group

Bimosiamose Cream

Active Comparator group

Treatment:

Drug: Bimosiamose Cream

Placebo Cream

Placebo Comparator group

Treatment:

Drug: Placebo Cream